TD Cowen analyst Joseph Thome raised the firm’s price target on Alkermes (ALKS) to $38 from $35. The firm said total Q4 revenue came in above expectations supported by beats from Vivitrol and Aristada as well as solid performance from Lybalvi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes price target raised to $34 from $33 at BofA
- Alkermes: Stability with Limited Upside Amid Program Expectations and Competitive Pressures
- Alkermes plc Reports Strong 2024 Financial Results
- Alkermes’ Strong Financial Performance and Future Growth Prospects Drive Buy Rating
- Alkermes sees FY25 revenue $1.340B-$1.430B, consensus $1.41B